clinical trial · NCT04648202
FS120 Phase 1/1b Study in Patients With Advanced Malignancies
Advanced CancerMetastatic CancerFS120
brief summary
This is a Phase 1/1b, multicenter, open label study to evaluate the Safety and Antitumor Activity of FS120, an OX40/CD137 Bispecific Antibody, Alone and in Combination with Pembrolizumab, in Subjects with Advanced Malignancies
started
Nov 18, 2020
primary completion
Mar 1, 2026
completion
Mar 1, 2026
last updated
Jun 27, 2025
official title
A Phase 1/1b Open-Label Study to Evaluate the Safety and Antitumor Activity of FS120, an OX40/CD137 Bispecific Antibody, Alone and in Combination With Pembrolizumab, in Subjects With Advanced Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol